R-Tech Ueno has completed the subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula eye-drops), in patients with
Alvine has initiated patient enrollment in a phase 2a, randomized, double-blind, placebo-controlled study, to assess the safety and efficacy of ALV003 for the treatment of celiac disease. The
GeneThera has reported a major expansion of its previously reported efforts to commercialize a diagnostic platform for Johne’s disease. The company said that it is preparing to enter
BioDelivery Sciences has revealed the issuance of US Patent No. 7,579,019, which will provide additional patent exclusivity for both Onsolis and BDSI’s Bema drug delivery technology platform, until
Delcath Systems, a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, has exceeded 90% enrollment (reaching 85 patients) for its
GenVec, a bio-pharmaceutical company developing novel gene-based therapeutic drugs and vaccines, has received a phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of
Beth R Jacobson has filed a suit against Celgene. The lawsuit claims of misappropriation of an idea and unjust enrichment regarding the company’s sale of thalidomide (Thalomid and
Myriad Genetics has reported an increase in molecular diagnostic revenue by 47% to $326.5m for fiscal year ended June 30, 2009, compared to $222.9m for the fiscal year
Cellceutix has acquired the rights to the compound KM 732, which shows properties in the reduction of high blood pressure. Preliminary testing in rats revealed that test animals
Antares Pharma has announced that its partner, Teva Pharmaceutical has launched its new Tjet needle-free injector system for the administration of human growth hormone (hGH). Tjet will be
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.